By Vijay Kumar Malesu Reviewed by Susha Cheriyedath, M.Sc. Apr 22 2026 A head-to-head trial and lifetime US economic analysis examine whether tirzepatide or semaglutide may offer better long-term value for adults with obesity or overweight without type 2 diabetes. Study: Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial . Image Credit: Gecko Studio / Shutterstock In a recent study